Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer

BACKGROUND: Overcoming drug resistance is critical for increasing the survival rate of prostate cancer (PCa). Docetaxel is the first cytotoxic chemotherapeutical approved for treatment of PCa. However, 99% of PCa patients will develop resistance to docetaxel within 3 years. Understanding how resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnepp, Patricia M., Ahmed, Aqila, Escara-Wilke, June, Dai, Jinlu, Shelley, Greg, Keller, Jill, Mizokami, Atsushi, Keller, Evan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653542/
https://www.ncbi.nlm.nih.gov/pubmed/34879849
http://dx.doi.org/10.1186/s12885-021-09048-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653542/
https://www.ncbi.nlm.nih.gov/pubmed/34879849
http://dx.doi.org/10.1186/s12885-021-09048-0

Ejemplares similares